Did the pandemic change our personalities? Increased neuroticism among young adults seen: Study

Despite a long-standing hypothesis that personality traits are relatively impervious to environmental pressures, the COVID-19 pandemic may have altered the trajectory of personality across the United States, especially in younger adults, according to a new study published this week in the open-access journal PLOS ONE by Angelina Sutin of Florida State University College of Medicine, and colleagues.

Previous studies have generally found no associations between collective stressful events—such as earthquakes and hurricanes—and personality change. However, the coronavirus pandemic has affected the entire globe and nearly every aspect of life.

In the new study, the researchers used longitudinal assessments of personality from 7,109 people enrolled in the online Understanding America Study. They compared five-factor model personality traits—neuroticism, extraversion, openness, agreeableness and conscientiousness—between pre-pandemic measurements (May 2014 – February 2020) and assessments early (March – December 2020) or later (2021-2022) in the pandemic. A total of 18,623 assessments, or a mean of 2.62 per participant, were analyzed. Participants were 41.2% male and ranged in age from 18 to 109.

Crowd during Pandemic

A crowd of people at a pedestrian crossing./CREDIT:Brian Merrill, Pixabay, CC0(https://creativecommons.org/publicdomain/zero/1.0/)

Consistent with other studies, there were relatively few changes between pre-pandemic and 2020 personality traits, with only a small decline in neuroticism. However, there were declines in extraversion, openness, agreeableness, and conscientiousness when 2021-2022 data was compared to pre-pandemic personality. The changes were about one-tenth of a standard deviation, which is equivalent to about one decade of normative personality change. The changes were moderated by age, with younger adults showing disrupted maturity in the form of increased neuroticism and decreased agreeableness and conscientiousness, and the oldest group of adults showing no statistically significant changes in traits.

The authors conclude that if these changes are enduring, it suggests that population-wide stressful events can slightly bend the trajectory of personality, especially in younger adults.

The authors add: “There was limited personality change early in the pandemic but striking changes starting in 2021. Of most note, the personality of young adults changed the most, with marked increases in neuroticism and declines in agreeableness and conscientiousness. That is, younger adults became moodier and more prone to stress, less cooperative and trusting, and less restrained and responsible.”

Covid Update: India reports 5,664 fresh Covid cases, 35 deaths

 Sep 18 (IANS) India on Sunday reported 5,664 fresh Covid cases in the last 24 hrs, against 5,747 Covid cases reported on previous day, said the Union Health Ministry.

In the same period, the country has recorded 35 more Covid related deaths, taking the national fatalities tally to 5,28,337 as per the report.

Meanwhile, the active caseload of the country has marginally risen to 47,922 cases, accounting for 0.11 per cent of the country’s total positive cases.

The recovery of 4,555 patients in the last 24 hours took the cumulative tally to 4,39,57,929. Consequently, India’s recovery rate stands at 98.71 per cent.

Vaccine

Meanwhile, India’s Daily Positivity Rate has been reported to be 1.96 per cent, while the Weekly Positivity Rate in the country currently also stands at 1.79 per cent.

Also in the same period, a total of 2,89,228 tests were conducted across the country, increasing the overall tally to over 89.15 crore.

As of Sunday morning, India’s Covid-19 vaccination coverage exceeded 216.56 crore.

Over 4.08 crore adolescents have been administered the first dose of Covid-19 jab since the beginning of vaccination drive for this age bracket.

New ecology tools predict disease transmission among wildlife, humans

The rate that emerging wildlife diseases infect humans has steadily increased over the last three decades. Viruses, such as the global coronavirus pandemic and recent monkeypox outbreak, have heightened the urgent need for disease ecology tools to forecast when and where disease outbreaks are likely.

A University of South Florida assistant professor helped develop a methodology that will do just that – predict disease transmission from wildlife to humans, from one wildlife species to another and determine who is at risk of infection.

The methodology is a machine-learning approach that identifies the influence of variables, such as location and climate, on known pathogens. Using only small amounts of information, the system is able to identify community hot spots at risk of infection on both global and local scales.

coronavirus

“Our main goal is to develop this tool for preventive measures,” said co-principal investigator Diego Santiago-Alarcon, a USF assistant professor of integrative biology. “It’s difficult to have an all-purpose methodology that can be used to predict infections across all the diverse parasite systems, but with this research, we contribute to achieving that goal.”

With help from researchers at the Universiad Veracruzana and Instituto de Ecologia, located in Mexico, Santiago-Alarcon examined three host-pathogen systems – avian malaria, birds with West Nile virus and bats with coronavirus – to test the reliability and accuracy of the models generated by the methodology.

The team found that for the three systems, the species most frequently infected was not necessarily the most susceptible to the disease. To better pinpoint hosts with higher risk of infection, it was important to identify relevant factors, such as climate and evolutionary relationships.

By integrating geographic, environmental and evolutionary development variables, the researchers identified host species that have previously not been recorded as infected by the parasite under study, providing a way to identify susceptible species and eventually mitigate pathogen risk.

“We feel confident that the methodology is successful, and it can be applied widely to many host-pathogen systems,” Santiago-Alarcon said. “We now enter into a phase of improvement and refinement.”

The results, published in the Proceedings of the National Academy of Sciences, prove the methodology is able to provide reliable global predictions for the studied host–pathogen systems, even when using a small amount of information. This new approach will help direct infectious disease surveillance and field efforts, providing a cost-effective strategy to better determine where to invest limited disease resources.

Bats/wikipedia

Predicting what kind of pathogen will produce the next medical or veterinary infection is challenging, but necessary. As the rate of human impact on natural environments increases, opportunity for novel diseases will continue to rise.

“Humanity, and indeed biodiversity in general, are experiencing more and more infectious disease challenges as a result of our incursion and destruction of the natural order worldwide through things like deforestation, global trade and climate change,” said Andrés Lira-Noriega, research fellow at the Instituto de Ecologia. “This imposes the need of having tools like the one we are publishing to help us predict where new threats in terms of new pathogens and their reservoirs may occur or arise.”

The team plans to continue their research to further test the methodology on additional host-pathogen systems and extend the study of disease transmission to predict future outbreaks. The goal is to make the tool easily accessible through an app for the scientific community by the end of 2022.

India’s first Nasal Vaccine against COVID- 19 gets nod for emergency use

Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC) has announced approval from DCGI for emergency use authorization first of its kind intranasal COVID-19 Vaccine to Bharat Biotech (BBIL).

Supported by DBT and BIRAC under the aegis of Mission COVID Suraksha, the mission was launched by DBT and implemented by BIRAC to reinforce and accelerate COVID-19 vaccine development efforts. Scientific leadership at various levels of vaccine development was provided by DBT laboratories and BIRAC. This is the fourth success story for the Covid-19 vaccine under mission Covid Suraksha.

BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. It consists of a replication deficient ChAd vector expressing the stabilized Spike SARS-CoV-2 (Wuhan variant).

DBT’s Autonomous Institute, National Institute of Immunology (NII), New Delhi utilized their “Human Immune Monitoring and T-cell Immunoassay Platform” to examine the vaccine-induced SARS-CoV-2-specific systemic and mucosal cellular immune responses the trial participants.

Interactive Research School for Health Affairs (IRSHA), Pune completed the Plaque Reduction Neutralization Assay (PRNT) to quantify the neutralizing antibody for the virus from three trial sites.

Covid Suraksha

Dr Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC speaking on the subject said that “The Department through Mission COVID Suraksha, is committed to the development of safe and efficacious COVID-19 vaccines.

BBV154 COVID Vaccine is the first intranasal vaccine approved by DCGI for primary immunization against COVID-19 in the 18+ age group for restricted use in emergency situation being developed in the country under Mission COVID Suraksha and adds to India’s COVID-19 vaccine series.

“This is an excellent example of Aatmanirbharta initiative of the Government of India. I congratulate our scientists for partnering with Bharat Biotech and providing scientific leadership throughout the development of first intranasal COVID-19 vaccine,” said Gokhale.

Mobile phone app accurately detects COVID-19 infection in people’s voices

Artificial intelligence (AI) can be used to detect COVID-19 infection in people’s voices by means of a mobile phone app, according to research to be presented on Monday at the European Respiratory Society International Congress in Barcelona, Spain [1].

The AI model used in this research is more accurate than lateral flow/rapid antigen tests and is cheap, quick and easy to use, which means it can be used in low-income countries where PCR tests are expensive and/or difficult to distribute.

Ms Wafaa Aljbawi, a researcher at the Institute of Data Science, Maastricht University, The Netherlands, told the congress that the AI model was accurate 89% of the time, whereas the accuracy of lateral flow tests varied widely depending on the brand. Also, lateral flow tests were considerably less accurate at detecting COVID infection in people who showed no symptoms.

COVID-19 infection usually affects the upper respiratory track and vocal cords, leading to changes in a person’s voice.

Covid/commons.wikimedia.org

“These promising results suggest that simple voice recordings and fine-tuned AI algorithms can potentially achieve high precision in determining which patients have COVID-19 infection,” she said.Moreover, they enable remote, virtual testing and have a turnaround time of less than a minute. They could be used, for example, at the entry points for large gatherings, enabling rapid screening of the population.”

The app is installed on the user’s mobile phone, the participants report some basic information about demographics, medical history and smoking status, and then are asked to record some respiratory sounds. These include coughing three times, breathing deeply through their mouth three to five times, and reading a short sentence on the screen three times.

The researchers used a voice analysis technique called Mel-spectrogram analysis, which identifies different voice features such as loudness, power and variation over time.

“In this way we can decompose the many properties of the participants’ voices,” said Ms Aljbawi. “In order to distinguish the voice of COVID-19 patients from those who did not have the disease, we built different artificial intelligence models and evaluated which one worked best at classifying the COVID-19 cases.”

Its overall accuracy was 89%, its ability to correctly detect positive cases (the true positive rate or “sensitivity”) was 89%, and its ability to correctly identify negative cases (the true negative rate or “specificity”) was 83%.

“These results show a significant improvement in the accuracy of diagnosing COVID-19 compared to state-of-the-art tests such as the lateral flow test,” said Ms Aljbawi.

The patients were “high engagers”, who had been using the app weekly over months or even years to record their symptoms and other health information, record medication, set reminders, and have access to up-to-date health and lifestyle information. Doctors can assess the data via a clinician dashboard, enabling them to provide oversight, co-management and remote monitoring.